[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Domperidone.]
[J01EC02, sulfadiazine, The metabolism of Domperidone can be decreased when combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Domperidone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Domperidone.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Domperidone.]
[N06DA01, tacrine, The metabolism of Domperidone can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Domperidone.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Domperidone.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Domperidone.]
[G03BA03, testosterone, The metabolism of Domperidone can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Domperidone is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Domperidone.]
[A04AD10, dronabinol, The metabolism of Domperidone can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Domperidone.]
[L04AX02, thalidomide, The metabolism of Domperidone can be increased when combined with Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Domperidone.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Domperidone.]
[P02CA02, thiabendazole, The metabolism of Domperidone can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Domperidone.]
[L01AC01, thiotepa, The metabolism of Domperidone can be decreased when combined with Thiotepa.]
[N05AC02, thioridazine, The metabolism of Domperidone can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Domperidone.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Domperidone.]
[B01AC05, ticlopidine, The metabolism of Domperidone can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Domperidone.]
[V04CA01, tolbutamide, The metabolism of Domperidone can be decreased when combined with Tolbutamide.]
[N02AX02, tramadol, The therapeutic efficacy of Domperidone can be decreased when used in combination with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Tranylcypromine is combined with Domperidone.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Domperidone.]
[L01XF01, tretinoin, The metabolism of Domperidone can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Domperidone can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, The metabolism of Domperidone can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The metabolism of Domperidone can be decreased when combined with Triazolam.]
[A03AB12, mepenzolate, The therapeutic efficacy of Domperidone can be decreased when used in combination with Mepenzolate.]
[N05AB06, trifluoperazine, The metabolism of Domperidone can be decreased when combined with Trifluoperazine.]
[N05AA05, triflupromazine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Triflupromazine.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Domperidone can be decreased when used in combination with Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Domperidone can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Domperidone.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Domperidone.]
[J01EA01, trimethoprim, The metabolism of Domperidone can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Domperidone.]
[R06AC04, tripelennamine, The metabolism of Domperidone can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Domperidone.]
[A03BB01, butylscopolamine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Domperidone can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Domperidone can be decreased when combined with Vilazodone.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Domperidone.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Vandetanib.]
[L02BX03, abiraterone, The serum concentration of Domperidone can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Domperidone can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Domperidone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Domperidone can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Domperidone can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Domperidone.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Domperidone.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Domperidone.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Domperidone.]
[C08DA01, verapamil, The metabolism of Domperidone can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Domperidone can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Domperidone can be decreased when combined with Vinblastine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Domperidone.]
[B01AA03, warfarin, The metabolism of Domperidone can be decreased when combined with Warfarin.]
[J05AF01, zidovudine, The metabolism of Domperidone can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Domperidone can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Domperidone can be increased when it is combined with Vemurafenib.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Domperidone.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Domperidone.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Domperidone.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Ziprasidone.]
[G04BD07, tolterodine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Tolterodine.]
[C07AB03, atenolol, The metabolism of Domperidone can be decreased when combined with Atenolol.]
[L03AB11, peginterferon alfa-2a, The metabolism of Domperidone can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Domperidone can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Domperidone.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Domperidone.]
[H02AB11, prednylidene, The metabolism of Domperidone can be increased when combined with Prednylidene.]
[L04AX01, azathioprine, The metabolism of Domperidone can be decreased when combined with Azathioprine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Domperidone.]
[A08AA11, lorcaserin, The metabolism of Domperidone can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Domperidone can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Domperidone can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Domperidone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Domperidone can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Domperidone can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The serum concentration of Domperidone can be decreased when it is combined with Teriflunomide.]
[J05AE04, nelfinavir, The metabolism of Domperidone can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Domperidone.]
[N04BD02, rasagiline, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Rasagiline is combined with Domperidone.]
[C08CA13, lercanidipine, The metabolism of Domperidone can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Domperidone can be decreased when combined with Donepezil.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Domperidone.]
[N02CC03, zolmitriptan, The metabolism of Domperidone can be decreased when combined with Zolmitriptan.]
[R06AC06, thonzylamine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Thonzylamine.]
[G04BD10, darifenacin, The therapeutic efficacy of Domperidone can be decreased when used in combination with Darifenacin.]
[L01EX07, cabozantinib, The metabolism of Domperidone can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Domperidone.]
[G04BE03, sildenafil, The metabolism of Domperidone can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Domperidone.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Domperidone.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Domperidone.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Domperidone.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Domperidone.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Domperidone can be decreased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Domperidone.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Domperidone.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Domperidone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Domperidone.]
[A06AX06, tegaserod, The metabolism of Domperidone can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The metabolism of Domperidone can be decreased when combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Domperidone can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Domperidone can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Domperidone is combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Domperidone can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Domperidone can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Domperidone.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Domperidone.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Domperidone.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Domperidone.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Domperidone.]
[J05AP05, simeprevir, The metabolism of Domperidone can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The metabolism of Domperidone can be decreased when combined with Dapagliflozin.]
[C07AB04, acebutolol, The metabolism of Domperidone can be decreased when combined with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Domperidone.]
[A16AA07, metreleptin, The metabolism of Domperidone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Domperidone can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Domperidone can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Domperidone can be decreased when combined with Betaxolol.]
[C10AB02, bezafibrate, The metabolism of Domperidone can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Domperidone can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Domperidone.]
[A03BA03, hyoscyamine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Domperidone.]
[L01XH04, belinostat, The metabolism of Domperidone can be increased when combined with Belinostat.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Domperidone.]
[D11AA01, glycopyrronium, The therapeutic efficacy of Domperidone can be decreased when used in combination with Glycopyrronium.]
[A16AX10, eliglustat, The metabolism of Domperidone can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Domperidone can be decreased when combined with Oritavancin.]
[N04AA02, biperiden, The therapeutic efficacy of Domperidone can be decreased when used in combination with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Domperidone.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Domperidone.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Domperidone.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Domperidone.]
[L04AC10, secukinumab, The metabolism of Domperidone can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Domperidone.]
[L01XH03, panobinostat, The metabolism of Domperidone can be decreased when combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Domperidone.]
[N02BE01, acetaminophen, The metabolism of Domperidone can be decreased when combined with Acetaminophen.]
[A03AA09, difemerine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Domperidone can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Domperidone.]
[A04AD14, rolapitant, The metabolism of Domperidone can be decreased when combined with Rolapitant.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Domperidone.]
[J02AC05, isavuconazole, The metabolism of Domperidone can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Domperidone can be decreased when it is combined with Osimertinib.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Domperidone.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Domperidone.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Domperidone.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Domperidone.]
[L01XX52, venetoclax, The metabolism of Domperidone can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Domperidone.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Domperidone.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Domperidone.]
[A05AA04, obeticholic acid, The metabolism of Domperidone can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The metabolism of Domperidone can be decreased when combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Domperidone.]
[N07BC01, buprenorphine, The metabolism of Domperidone can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Domperidone.]
[N05BE01, buspirone, The metabolism of Domperidone can be decreased when combined with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Domperidone.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Domperidone.]
[S01GX07, azelastine, The metabolism of Domperidone can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Domperidone can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Domperidone.]
[L01EF02, ribociclib, The metabolism of Domperidone can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Domperidone.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Domperidone is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Domperidone.]
[N06BC01, caffeine, The metabolism of Domperidone can be decreased when combined with Caffeine.]
[J01XX08, linezolid, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Linezolid is combined with Domperidone.]
[J05AE09, tipranavir, The metabolism of Domperidone can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Domperidone.]
[L04AB02, infliximab, The metabolism of Domperidone can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Domperidone can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Domperidone.]
[N04BD03, safinamide, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Safinamide is combined with Domperidone.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Domperidone.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Domperidone.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Domperidone.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Domperidone.]
[J05AG03, efavirenz, The metabolism of Domperidone can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Domperidone.]
[N04AA11, bornaprine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Bornaprine.]
[R03BA02, budesonide, The metabolism of Domperidone can be increased when combined with Budesonide.]
[L01EL02, acalabrutinib, The metabolism of Domperidone can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Domperidone can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Domperidone.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Domperidone.]
[N01BX04, capsaicin, The metabolism of Domperidone can be increased when combined with Capsaicin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Domperidone.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Domperidone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Domperidone.]
[A03AA03, camylofine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Domperidone.]
[L03AB06, interferon alfa-n1, The metabolism of Domperidone can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The metabolism of Domperidone can be decreased when combined with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Domperidone can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Domperidone can be increased when combined with Avatrombopag.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Domperidone.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Domperidone.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Domperidone.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Domperidone.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Domperidone.]
[N03AX17, stiripentol, The metabolism of Domperidone can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Domperidone can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Domperidone.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Domperidone.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Domperidone.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Chlorphenoxamine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Domperidone.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Domperidone.]
[R03BB08, revefenacin, The therapeutic efficacy of Domperidone can be decreased when used in combination with Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Domperidone.]
[L04AA39, emapalumab, The metabolism of Domperidone can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Domperidone can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Domperidone.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Domperidone.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Domperidone.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Domperidone.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Domperidone.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Domperidone.]
[J01FA09, clarithromycin, The metabolism of Domperidone can be decreased when combined with Clarithromycin.]
[N05BA09, clobazam, The metabolism of Domperidone can be decreased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Domperidone can be increased when combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Domperidone can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Domperidone can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Domperidone can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Domperidone can be decreased when combined with Alpelisib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Domperidone.]
[M03BX08, cyclobenzaprine, The metabolism of Domperidone can be decreased when combined with Cyclobenzaprine.]
[L01EJ02, fedratinib, The metabolism of Domperidone can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Domperidone can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Domperidone.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Domperidone.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Domperidone.]
[A10AE03, insulin, regular, pork, The metabolism of Domperidone can be increased when combined with Insulin pork.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Domperidone.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Domperidone.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Domperidone.]
[N03AX25, cenobamate, The serum concentration of Domperidone can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Domperidone can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Domperidone.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Domperidone.]
[N05CM21, lemborexant, The serum concentration of Domperidone can be decreased when it is combined with Lemborexant.]
[M01AX21, diacetylrhein, The metabolism of Domperidone can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Domperidone.]
[H02CA02, osilodrostat, The metabolism of Domperidone can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Domperidone can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Domperidone can be decreased when combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Domperidone can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Domperidone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Domperidone.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Domperidone.]
[N02CC06, eletriptan, The metabolism of Domperidone can be decreased when combined with Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Domperidone can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Domperidone can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Domperidone.]
[C01BD07, dronedarone, Domperidone may increase the QTc-prolonging activities of Dronedarone.]
[S03AA08, chloramphenicol, The metabolism of Domperidone can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Domperidone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Domperidone.]
[A03AA08, dihexyverine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Domperidone can be decreased when combined with Capmatinib.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Domperidone.]
[D07XB03, fluprednidene, The metabolism of Domperidone can be increased when combined with Fluprednidene.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Domperidone.]
[G04BD09, trospium, The therapeutic efficacy of Domperidone can be decreased when used in combination with Trospium.]
[L01EX22, selpercatinib, The serum concentration of Domperidone can be increased when it is combined with Selpercatinib.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Domperidone.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be decreased when combined with Domperidone.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Domperidone.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Domperidone.]
[P01BB01, proguanil, The metabolism of Domperidone can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Domperidone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Domperidone.]
[P01BA01, chloroquine, The metabolism of Domperidone can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Domperidone can be decreased when combined with Pralsetinib.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Domperidone.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Chlorpromazine.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Domperidone can be decreased when used in combination with Chlorprothixene.]
[M03BB03, chlorzoxazone, The metabolism of Domperidone can be decreased when combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Domperidone can be decreased when combined with Cholecalciferol.]
[B06AC06, berotralstat, The metabolism of Domperidone can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Domperidone can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Domperidone.]
[P03AX07, abametapir, The serum concentration of Domperidone can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, The metabolism of Domperidone can be increased when combined with Trilaciclib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Domperidone.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Domperidone.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Domperidone.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Domperidone.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Domperidone.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Domperidone.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Domperidone.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Domperidone can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Domperidone can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Domperidone.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Domperidone.]
[L01XX73, sotorasib, The serum concentration of Domperidone can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Domperidone.]
[L01XA01, cisplatin, The metabolism of Domperidone can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Citalopram is combined with Domperidone.]
[H01AC07, somapacitan, The metabolism of Domperidone can be increased when combined with Somapacitan.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Domperidone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Domperidone is combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The metabolism of Domperidone can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Domperidone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Domperidone.]
[N06AX25, St. John's wort extract, The metabolism of Domperidone can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Domperidone can be decreased when combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Domperidone.]
[B06AX04, mitapivat, The metabolism of Domperidone can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The metabolism of Domperidone can be decreased when combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Domperidone.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Domperidone.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Domperidone.]
[C01EB24, mavacamten, The serum concentration of Domperidone can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Domperidone.]
[H01CC04, linzagolix, The serum concentration of Domperidone can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Domperidone.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Domperidone.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Domperidone.]
[N05AH02, clozapine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Clozapine.]
[H01AC08, somatrogon, The metabolism of Domperidone can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Domperidone can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Domperidone can be decreased when combined with Codeine.]
[A03AB10, hexocyclium, The therapeutic efficacy of Domperidone can be decreased when used in combination with Hexocyclium.]
[A03BB06, homatropine methylbromide, The therapeutic efficacy of Domperidone can be decreased when used in combination with Homatropine methylbromide.]
[L04AA13, leflunomide, The serum concentration of Domperidone can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Domperidone.]
[A10BX03, nateglinide, The metabolism of Domperidone can be decreased when combined with Nateglinide.]
[J01FA15, telithromycin, The metabolism of Domperidone can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Domperidone.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Domperidone.]
[N02CC05, almotriptan, The metabolism of Domperidone can be decreased when combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Domperidone can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The metabolism of Domperidone can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Domperidone.]
[L01EA01, imatinib, The serum concentration of Domperidone can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Domperidone can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Domperidone.]
[N03AX09, lamotrigine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Domperidone.]
[S01BA03, cortisone, The metabolism of Domperidone can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Domperidone.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Domperidone.]
[R06AX13, loratadine, The metabolism of Domperidone can be decreased when combined with Loratadine.]
[C08CA11, manidipine, The metabolism of Domperidone can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Mebeverine.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Domperidone.]
[H02AB15, meprednisone, The metabolism of Domperidone can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Domperidone.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Domperidone.]
[N04AA03, methixene, The therapeutic efficacy of Domperidone can be decreased when used in combination with Metixene.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Domperidone.]
[C03DA04, eplerenone, The metabolism of Domperidone can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Domperidone.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Domperidone.]
[N06AX07, minaprine, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Minaprine is combined with Domperidone.]
[S01XA18, cyclosporine, The metabolism of Domperidone can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Moclobemide is combined with Domperidone.]
[N06BA07, modafinil, The metabolism of Domperidone can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Domperidone.]
[C10AA07, rosuvastatin, The metabolism of Domperidone can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Domperidone can be decreased when combined with Conivaptan.]
[J05AF10, entecavir, The metabolism of Domperidone can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Domperidone.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Domperidone.]
[L01AX04, dacarbazine, The metabolism of Domperidone can be decreased when combined with Dacarbazine.]
[G03XA01, danazol, The metabolism of Domperidone can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Domperidone can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Domperidone can be increased when combined with Daunorubicin.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Domperidone.]
[M01AX01, nabumetone, The metabolism of Domperidone can be decreased when combined with Nabumetone.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Domperidone.]
[N06AX06, nefazodone, The metabolism of Domperidone can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Domperidone can be decreased when combined with Nilutamide.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Domperidone.]
[N06AB10, escitalopram, The serum concentration of Domperidone can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The therapeutic efficacy of Domperidone can be decreased when used in combination with Solifenacin.]
[N06AA01, desipramine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Desipramine.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Domperidone.]
[N03AF02, oxcarbazepine, The metabolism of Domperidone can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Domperidone can be increased when combined with Dexamethasone.]
[N04AA08, dexetimide, The therapeutic efficacy of Domperidone can be decreased when used in combination with Dexetimide.]
[G04BD04, oxybutynin, The therapeutic efficacy of Domperidone can be decreased when used in combination with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Domperidone.]
[A03AA01, oxyphencyclimine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Domperidone can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Domperidone can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The metabolism of Domperidone can be decreased when combined with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Domperidone can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Domperidone can be decreased when combined with Paramethadione.]
[N06AB05, paroxetine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Domperidone can be decreased when combined with Clopidogrel.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Domperidone.]
[N05BA01, diazepam, The metabolism of Domperidone can be decreased when combined with Diazepam.]
[S01BC03, diclofenac, The metabolism of Domperidone can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Domperidone.]
[A03AA07, dicyclomine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Dicyclomine.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Domperidone.]
[A10BG03, pioglitazone, The metabolism of Domperidone can be decreased when combined with Pioglitazone.]
[A03AB14, pipenzolate, The therapeutic efficacy of Domperidone can be decreased when used in combination with Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Domperidone.]
[L02AA01, diethylstilbestrol, The metabolism of Domperidone can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Domperidone can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Domperidone can be increased when combined with Difluocortolone.]
[A03AB11, poldine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Poldine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Domperidone.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Domperidone.]
[C02DB01, dihydralazine, The metabolism of Domperidone can be decreased when combined with Dihydralazine.]
[N02CA01, dihydroergotamine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Domperidone.]
[J05AE08, atazanavir, The metabolism of Domperidone can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Domperidone.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Domperidone.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Domperidone.]
[R06AB03, dimethindene, The therapeutic efficacy of Domperidone can be decreased when used in combination with Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Domperidone can be decreased when combined with Dimethyl sulfoxide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Domperidone.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Domperidone.]
[R06AA02, diphenhydramine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Domperidone can be decreased when combined with Quazepam.]
[A03FA02, cisapride, The metabolism of Domperidone can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Domperidone.]
[N05AL04, remoxipride, The metabolism of Domperidone can be decreased when combined with Remoxipride.]
[C01BA03, disopyramide, The therapeutic efficacy of Domperidone can be decreased when used in combination with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Domperidone.]
[S02AA12, rifamycin SV, The metabolism of Domperidone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Domperidone can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The metabolism of Domperidone can be decreased when combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Domperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Domperidone.]
[N01BB09, ropivacaine, The metabolism of Domperidone can be decreased when combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Domperidone.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Domperidone.]
[A04AD12, aprepitant, The metabolism of Domperidone can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Domperidone.]
[G04BE08, tadalafil, The metabolism of Domperidone can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The metabolism of Domperidone can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Domperidone.]
[C01EB18, ranolazine, The serum concentration of Domperidone can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Domperidone can be decreased when combined with Salmeterol.]
[S01AA13, fusidic acid, The metabolism of Domperidone can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Domperidone.]
[M01AG01, mefenamic acid, The metabolism of Domperidone can be decreased when combined with Mefenamic acid.]
[N06AA16, dothiepin, The therapeutic efficacy of Domperidone can be decreased when used in combination with Dosulepin.]
[N06AA12, doxepin, The therapeutic efficacy of Domperidone can be decreased when used in combination with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Domperidone can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Doxylamine.]
[N06AB06, sertraline, The metabolism of Domperidone can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Domperidone.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Domperidone.]
[C10AA01, simvastatin, The metabolism of Domperidone can be decreased when combined with Simvastatin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Domperidone.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Domperidone.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Domperidone can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Terodiline.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Domperidone.]
[G04BD01, emepronium, The therapeutic efficacy of Domperidone can be decreased when used in combination with Emepronium.]
[N06AG03, toloxatone, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Toloxatone is combined with Domperidone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Domperidone.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Domperidone.]
[C03CA04, torsemide, The metabolism of Domperidone can be decreased when combined with Torasemide.]
[A03AB08, tridihexethyl, The therapeutic efficacy of Domperidone can be decreased when used in combination with Tridihexethyl.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Domperidone.]
[N04AA12, tropatepine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Tropatepine.]
[J01MA04, enoxacin, The metabolism of Domperidone can be decreased when combined with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Domperidone can be decreased when combined with Vinorelbine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Domperidone.]
[N06AX16, venlafaxine, The metabolism of Domperidone can be decreased when combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Domperidone can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, The metabolism of Domperidone can be decreased when combined with Zolpidem.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Domperidone.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Domperidone.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Domperidone.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Domperidone.]
[C04AE01, ergoloid mesylates, USP, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Domperidone.]
[N02CA02, ergotamine, The metabolism of Domperidone can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Domperidone.]
[H05BX01, cinacalcet, The metabolism of Domperidone can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Domperidone can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Domperidone can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Domperidone can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Domperidone can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Domperidone can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Domperidone can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Domperidone can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Domperidone.]
[N04AA05, profenamine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Profenamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Domperidone.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Domperidone.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Domperidone.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Domperidone.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Domperidone.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Domperidone.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Domperidone.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Domperidone.]
[R06AX12, terfenadine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Terfenadine.]
[N06AX12, bupropion, The metabolism of Domperidone can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Domperidone can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Domperidone can be decreased when combined with Tocainide.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Domperidone.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Domperidone.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Domperidone.]
[P02CA03, albendazole, The metabolism of Domperidone can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Domperidone can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Domperidone.]
[N03AX26, fenfluramine, The metabolism of Domperidone can be decreased when combined with Fenfluramine.]
[N02AB03, fentanyl, The metabolism of Domperidone can be decreased when combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Domperidone.]
[N07AX03, cevimeline, The metabolism of Domperidone can be decreased when combined with Cevimeline.]
[G04BD02, flavoxate, The therapeutic efficacy of Domperidone can be decreased when used in combination with Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Domperidone.]
[J02AC01, fluconazole, The metabolism of Domperidone can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Domperidone.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Domperidone.]
[D07AC08, fluocinonide, The metabolism of Domperidone can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Domperidone can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Domperidone can be decreased when combined with Ethanol.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Domperidone.]
[N06AB03, fluoxetine, The serum concentration of Domperidone can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Domperidone can be decreased when combined with Fluphenazine.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Domperidone.]
[L02BB01, flutamide, The metabolism of Domperidone can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Domperidone.]
[G01AX06, furazolidone, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Furazolidone is combined with Domperidone.]
[J05AE10, darunavir, The metabolism of Domperidone can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Domperidone can be decreased when combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Domperidone.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Domperidone.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Domperidone.]
[C10AB04, gemfibrozil, The metabolism of Domperidone can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Domperidone.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Domperidone.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Domperidone.]
[N04BC06, cabergoline, The therapeutic efficacy of Cabergoline can be decreased when used in combination with Domperidone.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Domperidone.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Domperidone.]
[N01AH02, alfentanil, The metabolism of Domperidone can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Domperidone.]
[A10BB01, glyburide, The metabolism of Domperidone can be decreased when combined with Glyburide.]
[N05CM18, dexmedetomidine, The metabolism of Domperidone can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Domperidone.]
[C02CA04, doxazosin, The metabolism of Domperidone can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Domperidone.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Domperidone.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Domperidone.]
[P01BX01, halofantrine, The metabolism of Domperidone can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Haloperidol.]
[N01AB01, halothane, The metabolism of Domperidone can be decreased when combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Domperidone.]
[N05AH04, quetiapine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Domperidone can be decreased when combined with Irinotecan.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Domperidone.]
[J05AG01, nevirapine, The metabolism of Domperidone can be increased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Domperidone.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Domperidone.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Domperidone.]
[R05DA03, hydrocodone, The metabolism of Domperidone can be decreased when combined with Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Domperidone can be increased when combined with Hydrocortisone.]
[G04BD06, propiverine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Domperidone.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Domperidone can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Domperidone can be decreased when combined with Ibuprofen.]
[L01DB06, idarubicin, The metabolism of Domperidone can be decreased when combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Domperidone.]
[H01AC02, somatrem, The metabolism of Domperidone can be increased when combined with Somatrem.]
[N06AA02, imipramine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Domperidone.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Domperidone.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Domperidone.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Domperidone.]
[L03AB04, interferon alfa-2a, The metabolism of Domperidone can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Domperidone can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The metabolism of Domperidone can be decreased when combined with Milnacipran.]
[A03AA30, piperidolate, The therapeutic efficacy of Domperidone can be decreased when used in combination with Piperidolate.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Domperidone.]
[N05BA12, alprazolam, The metabolism of Domperidone can be decreased when combined with Alprazolam.]
[N05CH02, ramelteon, The metabolism of Domperidone can be decreased when combined with Ramelteon.]
[R06AE01, buclizine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Buclizine.]
[C10AA06, cerivastatin, The metabolism of Domperidone can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Domperidone.]
[C07AA01, alprenolol, The metabolism of Domperidone can be decreased when combined with Alprenolol.]
[L03AB09, interferon alfacon-1, The metabolism of Domperidone can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Domperidone.]
[N06AF05, iproniazid, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Iproniazid is combined with Domperidone.]
[J05AB13, penciclovir, The metabolism of Domperidone can be decreased when combined with Penciclovir.]
[N06AF01, isocarboxazid, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Isocarboxazid is combined with Domperidone.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Domperidone.]
[N04BX02, entacapone, The metabolism of Domperidone can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Domperidone can be decreased when combined with Isoniazid.]
[N06AX18, reboxetine, The metabolism of Domperidone can be decreased when combined with Reboxetine.]
[H01AC01, somatropin, The metabolism of Domperidone can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Domperidone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Domperidone.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Domperidone.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Domperidone.]
[N05AH03, olanzapine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Domperidone can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Domperidone can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Domperidone can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Domperidone.]
[N04BC09, rotigotine, The metabolism of Domperidone can be decreased when combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Domperidone.]
[C07AG01, labetalol, The metabolism of Domperidone can be decreased when combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Domperidone.]
[G03AD01, levonorgestrel, The metabolism of Domperidone can be decreased when combined with Levonorgestrel.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Domperidone.]
[S02DA01, lidocaine, The metabolism of Domperidone can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Domperidone.]
[N06BA13, armodafinil, The metabolism of Domperidone can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The therapeutic efficacy of Lisuride can be decreased when used in combination with Domperidone.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Domperidone.]
[C10AA02, lovastatin, The metabolism of Domperidone can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Domperidone.]
[L01EA03, nilotinib, The metabolism of Domperidone can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The therapeutic efficacy of Domperidone can be decreased when used in combination with Maprotiline.]
[R06AE05, meclizine, The metabolism of Domperidone can be decreased when combined with Meclizine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Domperidone.]
[N05CH01, melatonin, The metabolism of Domperidone can be decreased when combined with Melatonin.]
[N06DX01, memantine, The metabolism of Domperidone can be decreased when combined with Memantine.]
[N02AB02, meperidine, The metabolism of Domperidone can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Domperidone can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Domperidone can be decreased when combined with Methylphenobarbital.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Domperidone.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Domperidone.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Domperidone.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Domperidone.]
[A03AB07, methantheline, The therapeutic efficacy of Domperidone can be decreased when used in combination with Methantheline.]
[G02CB05, metergoline, The therapeutic efficacy of Metergoline can be decreased when used in combination with Domperidone.]
[H03BB02, methimazole, The metabolism of Domperidone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Domperidone can be decreased when combined with Pemetrexed.]
[L04AX03, methotrexate, The excretion of Methotrexate can be decreased when combined with Domperidone.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Domperidone can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Domperidone can be decreased when combined with Methoxyflurane.]
[V04CG05, methylene blue, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Methylene blue is combined with Domperidone.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Domperidone.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Domperidone.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Domperidone.]
[C07AB02, metoprolol, The metabolism of Domperidone can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Domperidone.]
[C01BB02, mexiletine, The metabolism of Domperidone can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Domperidone.]
[S02AA13, miconazole, The metabolism of Domperidone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Domperidone.]
[N05CD08, midazolam, The metabolism of Domperidone can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The serum concentration of Domperidone can be increased when it is combined with Mifepristone.]
[L01XX23, mitotane, The metabolism of Domperidone can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Domperidone can be decreased when combined with Lisdexamfetamine.]
[C01BD01, amiodarone, The metabolism of Domperidone can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The therapeutic efficacy of Domperidone can be decreased when used in combination with Amitriptyline.]
[N02AA01, morphine, The metabolism of Domperidone can be decreased when combined with Morphine.]
[A04AA05, palonosetron, The metabolism of Domperidone can be decreased when combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Domperidone can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Domperidone can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Domperidone.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Domperidone.]
[G03XC01, raloxifene, The metabolism of Domperidone can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Domperidone.]
[L03AB08, interferon beta-1b, The metabolism of Domperidone can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Domperidone.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Domperidone.]
[J01CF06, nafcillin, The metabolism of Domperidone can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Domperidone can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Domperidone can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Domperidone can be decreased when combined with Amphetamine.]
[M02AA12, naproxen, The metabolism of Domperidone can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Domperidone can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Domperidone can be decreased when combined with Duloxetine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Domperidone.]
[A10BX02, repaglinide, The metabolism of Domperidone can be decreased when combined with Repaglinide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Domperidone.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The metabolism of Domperidone can be decreased when combined with Desvenlafaxine.]
[C10AD02, niacin, The metabolism of Domperidone can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Nialamide is combined with Domperidone.]
[C08CA04, nicardipine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Domperidone can be decreased when combined with Nicergoline.]
[P02DA01, niclosamide, The metabolism of Domperidone can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The metabolism of Domperidone can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Domperidone.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Domperidone.]
[C08CA07, nisoldipine, The metabolism of Domperidone can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Domperidone.]
[N05CF03, zaleplon, The metabolism of Domperidone can be decreased when combined with Zaleplon.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Domperidone.]
[G03DC02, norethindrone, The metabolism of Domperidone can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Domperidone.]
[N06AA10, nortriptyline, The therapeutic efficacy of Domperidone can be decreased when used in combination with Nortriptyline.]
[L03AB07, interferon beta-1a, The metabolism of Domperidone can be decreased when combined with Interferon beta-1a.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Domperidone.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Domperidone.]
[L04AC04, rilonacept, The metabolism of Domperidone can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Domperidone can be decreased when combined with Omeprazole.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Domperidone.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Domperidone.]
[G04CA02, tamsulosin, The metabolism of Domperidone can be decreased when combined with Tamsulosin.]
[P02BA02, oxamniquine, The metabolism of Domperidone can be decreased when combined with Oxamniquine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Domperidone.]
[C07AA02, oxprenolol, The metabolism of Domperidone can be decreased when combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Domperidone can be decreased when combined with Oxycodone.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Domperidone.]
[A03AB03, oxyphenonium, The therapeutic efficacy of Domperidone can be decreased when used in combination with Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Domperidone.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Asenapine.]
[M03AC01, pancuronium, The therapeutic efficacy of Domperidone can be decreased when used in combination with Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Domperidone.]
[H02AB05, paramethasone, The metabolism of Domperidone can be increased when combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Pargyline is combined with Domperidone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Domperidone.]
[G04BD11, fesoterodine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Fesoterodine.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be decreased when combined with Domperidone.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Domperidone.]
[N05CA01, pentobarbital, The metabolism of Domperidone can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The metabolism of Domperidone can be decreased when combined with Pentoxifylline.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Domperidone.]
[C08EX02, perhexiline, The metabolism of Domperidone can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Domperidone can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Domperidone.]
[N06AF03, phenelzine, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Phenelzine is combined with Domperidone.]
[A10BA01, phenformin, The metabolism of Domperidone can be decreased when combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Domperidone.]
[N03AA02, phenobarbital, The metabolism of Domperidone can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Domperidone.]
[S01GA05, phenylephrine, The metabolism of Domperidone can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Domperidone.]
[L04AB06, golimumab, The metabolism of Domperidone can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Domperidone.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Domperidone.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Domperidone.]
[C07AA03, pindolol, The metabolism of Domperidone can be decreased when combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Domperidone can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The metabolism of Domperidone can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Domperidone can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Domperidone can be decreased when combined with Pipotiazine.]
[A02BX03, pirenzepine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Domperidone.]
[S01BC06, piroxicam, The metabolism of Domperidone can be decreased when combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Domperidone.]
[N02CX01, pizotyline, The therapeutic efficacy of Domperidone can be decreased when used in combination with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Domperidone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Domperidone can be decreased when combined with Irbesartan.]
[D05AX05, tazarotene, The metabolism of Domperidone can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Domperidone can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Domperidone.]
[A03AE01, alosetron, The metabolism of Domperidone can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Domperidone can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Domperidone can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Domperidone.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Domperidone.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Domperidone.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Domperidone.]
[P02BA01, praziquantel, The metabolism of Domperidone can be decreased when combined with Praziquantel.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Domperidone.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Domperidone.]
[P01BA03, primaquine, The metabolism of Domperidone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Domperidone can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Domperidone can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Domperidone.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Domperidone.]
[S01HA05, procaine, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Procaine is combined with Domperidone.]
[L01XB01, procarbazine, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Procarbazine is combined with Domperidone.]
[C10AB05, fenofibrate, The metabolism of Domperidone can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Domperidone.]
[N04AA04, procyclidine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Procyclidine.]
[G03DA04, progesterone, The metabolism of Domperidone can be decreased when combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Domperidone.]
[A03AB05, propantheline, The therapeutic efficacy of Domperidone can be decreased when used in combination with Propantheline.]
[N05CM06, propiomazine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Domperidone.]
[N02AC04, propoxyphene, The metabolism of Domperidone can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Domperidone can be decreased when combined with Propranolol.]
[R03DC03, montelukast, The metabolism of Domperidone can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Domperidone.]
[N05AX12, aripiprazole, The therapeutic efficacy of Domperidone can be decreased when used in combination with Aripiprazole.]
[A03AB15, diphemanil, The therapeutic efficacy of Domperidone can be decreased when used in combination with Diphemanil.]
[A03AB09, isopropamide, The therapeutic efficacy of Domperidone can be decreased when used in combination with Isopropamide.]
[S01FA03, methscopolamine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Methscopolamine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Domperidone.]
[P01BD01, pyrimethamine, The metabolism of Domperidone can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Domperidone can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Quinidine.]
[P01BC01, quinine, The metabolism of Domperidone can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Domperidone can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The metabolism of Domperidone can be increased when combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Domperidone can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Domperidone.]
[S01FA02, scopolamine, The therapeutic efficacy of Domperidone can be decreased when used in combination with Scopolamine.]
[N05CA06, secobarbital, The metabolism of Domperidone can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Selegiline is combined with Domperidone.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Domperidone.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Domperidone.]
[C03DA01, spironolactone, The metabolism of Domperidone can be decreased when combined with Spironolactone.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Domperidone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Domperidone.]
[H02CA04, levoketoconazole, The metabolism of Domperidone can be decreased when combined with Levoketoconazole.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Domperidone can be decreased when used in combination with Ipratropium.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
